

CLINICAL STUDY PROTOCOL AGREEMENT**Protocol N°:** DNDi-6148-01 / OP105718.DND**Title:** A Phase 1, blinded, randomized, single centre, parallel-group, single-dose, dose-escalation, placebo-controlled study of the safety, tolerability, and pharmacokinetics of DNDi-6148 after oral dosing in healthy male subjects

The sponsor and the investigator agree to conduct the study in compliance with the clinical study protocol (and amendments), International Conference on Harmonization (ICH) guidelines for current Good Clinical Practice (cGCP) and applicable regulatory requirements.

Sponsor:

DRUGS FOR NEGLECTED DISEASES *initiative* (DNDi)
Chemin Louis Dunant, 15
1202 Geneva, Switzerland

As of March 1st, 2021, new address:
15 Chemin Camille-Vidart
1202 Geneva, Switzerland

Represented by:**Date:**
(dd-mmm-yyyy)**Signature :**

Sophie Delhomme,
Translational Manager, DNDi
Tel: +41 22 906 92 79 / +41 79 305 73 38

Jean-Yves Gillon, PharmD, PhD
Head of translational Sciences, DNDi
Tel: +41 22 906 92 30 / +41 79 324 61 24

Dr Byron Arana, MD, PhD
Medical responsible, DNDi
Tel : +41 22 906 92 58 / +41 79 276 22 83

Yves DONAZZOLO, MD, MSc
Principal Investigator
EUROFINS OPTIMED

Laure-Anne Giannone
Statistician
EUROFINS OPTIMED

25 FEB 2021

24FEB2021

DocuSigned by:

Laure Anne Giannone

22AFBDD402A94AA...